BIOCHINA 2026 BiOPartnering System Now Open: 1V1 Meeting Scheduling Live

The BIOCHINA 2026 BiOPartnering system is officially live, generating strong momentum ahead of the March event in Suzhou. Nearly 1,000 multinational corporations, pharmaceutical companies, biotech innovators, and investment institutions are already active on the platform. Starting today, participants can schedule one-on-one meetings to secure meaningful connections before the exhibition begins.

Why BiOPartnering Matters

BiOPartnering at BIOCHINA 2026 offers a targeted, efficient way to connect with key stakeholders across the biopharmaceutical ecosystem. Participants can engage directly with global MNC and pharmaceutical executives, biotech founders from China and overseas, investors, research organizations, upstream suppliers, and service providers. Through pre-arranged one-on-one meetings, attendees can maximize on-site time, prioritize high-value conversations, and turn a busy conference agenda into concrete collaboration opportunities.

Leading Participants Already on the Platform

Global leaders are actively booking meetings, including top multinational companies such as Bayer, Pfizer, Eli Lilly, Novartis, and Novo Nordisk. International pharmaceutical and business organizations including Sun Pharma, Dr. Reddy’s, Hikma, Asahi Kasei, Syneos Health, and Canadian trade bodies are also participating. High-quality Chinese innovators, including Gan & Lee Pharmaceuticals, InnoMed, and Qide Pharma, are among the domestic companies leveraging the platform for strategic connections.

January Group Registration Benefits

Group registration for BIOCHINA 2026 provides exclusive discounts and additional benefits, making it an ideal option for teams planning strategic meetings and collaborations.

Register now to secure your place: BIOCHINA 2026 Registration

For inquiries, full participant lists, or additional information about BiOPartnering access, please contact: biochina@enmore.com or +86 156 1892 1630 (WhatsApp).